Compare AU

Compare DRUG vs. BBAB

Compare shares and ETFs on the ASX that you can trade on Pearler.

BetaShares Global Healthcare ETF - Currency Hedged

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are DRUG and BBAB. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.

Community Stats

DRUG

BBAB

Popularity

Low

Low

Pearlers invested

64

1

Median incremental investment

$943.50

$993.50

Median investment frequency

Monthly

Monthly

Median total investment

$1,965.04

$1,015.41

Average age group

26 - 35

> 35


Key Summary

DRUG

BBAB

Strategy

DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars.

N/A

Top 3 holdings

CHF - SWISS FRANC (0 %)

AUD - AUSTRALIA DOLLAR (0 %)

DKK - DANISH KRONE (0 %)

BetaShares Geared Short Aus Gov Bond (Hedge Fund) (100 %)

Top 3 industries

Other (75.53 %)

Communication Services (33.53 %)

Health Care (24.47 %)

Top 3 countries

United States (23.96 %)

Ireland (0.52 %)

France (0.00 %)

Management fee

0.57 %

0 %


Key Summary

DRUG

BBAB

Issuer

BetaShares

Tracking index

Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD

Asset class

ETF

Stock

Management fee

0.57 %

0 %

Price

$8.56

$20.15

Size

$197.947 million

N/A

10Y return

N/A

N/A

Annual distribution/ dividend yield (5Y)

1.90 %

0.89 %

Market

ASX

ASX

First listed date

08/08/2016

05/12/2023

Purchase fee

$6.50

$6.50


Community Stats

DRUG

BBAB

Popularity

Low

Low

Pearlers invested

64

1

Median incremental investment

$943.50

$993.50

Median investment frequency

Monthly

Monthly

Median total investment

$1,965.04

$1,015.41

Average age group

26 - 35

> 35


Pros and Cons

DRUG

BBAB

Pros

  • Exposure to more markets and sectors

  • Higher price growth

  • Higher dividend/distribution yield

Cons

  • Exposure to 1 market and 1 sector only

  • Lower price growth

  • Lower dividend/distribution yield

DRUG

BBAB

Exposure to more markets and sectors

Exposure to 1 market and 1 sector only

Higher price growth

Lower price growth

Higher dividend/distribution yield

Lower dividend/distribution yield

Home